Selumetinib: the first ever approved drug for neurofibromatosis-1 related inoperable plexiform neurofibroma

被引:10
|
作者
Mukhopadhyay, Sabyasachi [1 ]
Maitra, Arpita [2 ]
Choudhury, Shouvik [2 ]
机构
[1] AMRI Hosp, Dept Neonatol, Kolkata, India
[2] Burdwan Med Coll, Dept Pharmacol, Burdwan 713104, W Bengal, India
关键词
Neurofibroma; tumour; medicine; neurological disorder;
D O I
10.1080/03007995.2021.1900089
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Plexiform neurofibroma (PN) is one of the most striking clinical features of neurofibromatosis 1. Growth of PN can occur at any stage of life but mostly in childhood and during hormonal changes. They arise from multiple nerve fascicles and may transform into malignant peripheral nerve sheath tumors. There was previously no approved medical therapy for tumor shrinkage or regression. Surgery is not always possible due to inaccessible location, involvement of vital tissue, optimal timing, and incomplete removal. Recently, the US Food and Drug Administration approved selumetinib for pediatric patients, 2 years of age and older, with neurofibromatosis type 1 who have symptomatic, inoperable tumor. Neurofibromin, a 2818 amino acid long cytoplasmic protein, is the product of the NF1 gene. It inhibits the activity of Ras GTPase proteins. Lack of functional neurofibromin in patients with NF1 leads to dysregulated Ras and tumorigenesis. RAS MAPK pathway is hyper activated in NF1. Selumetinib is an inhibitor of MEK1 and MEK2 proteins, which play an important role in the MAPK signaling pathway related to tumor growth. Approval was based on one pivotal, single-arm, phase II trial. 70% of participants experienced confirmed partial response of tumor shrinkage, and 68% also had improvement of related complications, and other studies have also shown beneficial responses. The major limitation of this molecule regarding its mechanism of action is the dose-dependent effect of MEK inhibition in growth of neurofibroma. Long-term safety and efficacy studies are to be done in the future to establish selumetininb as a useful medicine.
引用
收藏
页码:789 / 794
页数:6
相关论文
共 50 条
  • [1] Neurofibromatosis-1 uncommon plexiform neurofibroma
    Sacristán, EH
    Cavicchia, LM
    Magariños, R
    Martin, RJ
    Del Río, G
    Primatesta, P
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2003, 214 (1-2) : 74 - 74
  • [2] Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidity
    Gross, Andrea M.
    Glassberg, Brittany
    Wolters, Pamela L.
    Dombi, Eva
    Baldwin, Andrea
    Fisher, Michael J.
    Kim, AeRang
    Bornhorst, Miriam
    Weiss, Brian D.
    Blakeley, Jaishri O.
    Whitcomb, Patricia
    Paul, Scott M.
    Steinberg, Seth M.
    Venzon, David J.
    Martin, Staci
    Carbonell, Amanda
    Heisey, Kara
    Therrien, Janet
    Kapustina, Oxana
    Dufek, Anne
    Derdak, Joanne
    Smith, Malcolm A.
    Widemann, Brigitte C.
    [J]. NEURO-ONCOLOGY, 2022, 24 (11) : 1978 - 1988
  • [3] Inhibition of YAP Sensitizes the Selumetinib Treatment for Neurofibromatosis Type 1 Related Plexiform Neurofibroma
    Tian, Zhuowei
    You, Yuanhe
    Xiao, Meng
    Liu, Jialiang
    Xu, Guisong
    Ma, Chunyue
    Du, Zhong
    Wang, Yanan
    [J]. INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2023, 20 (01): : 125 - 135
  • [4] Safety and efficacy of selumetinib in pediatric and adult patients with neurofibromatosis type 1 and plexiform neurofibroma
    Kim, Hyery
    Yoon, Hee Mang
    Kim, Eun Key
    Ra, Young Shin
    Kim, Hyo-Won
    Yum, Mi-Sun
    Kim, Min-Jee
    Baek, Jae Suk
    Sung, Yu Sub
    Lee, Sang Min
    Lim, Hyeong-Seok
    Lee, Byung Joo
    Lim, Hyun Taek
    Kim, Dohyung
    Yoon, Jihee
    Bae, Hyunwoo
    Hwang, Soojin
    Choi, Yun-Ha
    Kim, Kyung Ah
    Choi, In Hee
    Lee, Seung Won
    Park, Su-Jung
    Lee, Beom Hee
    [J]. NEURO-ONCOLOGY, 2024,
  • [5] Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas
    Dombi, Eva
    Baldwin, Andrea
    Marcus, Leigh J.
    Fisher, Michael J.
    Weiss, Brian
    Kim, AeRang
    Whitcomb, Patricia
    Martin, Staci
    Aschbacher-Smith, Lindsey E.
    Rizvi, Tilat A.
    Wu, Jianqiang
    Ershler, Rachel
    Wolters, Pamela
    Therrien, Janet
    Glod, John
    Belasco, Jean B.
    Schorry, Elizabeth
    Brofferio, Alessandra
    Starosta, Amy J.
    Gillespie, Andrea
    Doyle, Austin L.
    Ratner, Nancy
    Widemann, Brigitte C.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (26): : 2550 - 2560
  • [6] Plexiform neurofibroma in type 1 neurofibromatosis
    Keehn, Connie A.
    Myers, Pearl
    Paidas, Charles N.
    Gilbert-Barness, Enid
    [J]. FETAL AND PEDIATRIC PATHOLOGY, 2006, 25 (02) : 87 - 93
  • [7] SELUMETINIB FOR SYMPTOMATIC, INOPERABLE PLEXIFORM NEUROFIBROMAS IN NEUROFIBROMATOSIS TYPE 1: A SINGLE-INSTITUTION EXPERIENCE
    Vazquez-Gomez, Felisa
    Perez-Somarriba, Marta
    Castellano, Serafin
    Moreno, Jose Luis
    Cartas, Susana
    Cantarin, Veronica
    Duat, Anna
    Borrego, Pedro
    Solis, Ines
    Valls, Isabel
    Hernandez, Angela
    Torrelo, Antonio
    Esteso, Borja
    Tamariz-Martel, Amalia
    Egea, Rosa Maria
    Blasco, Luis
    Colmenero, Isabel
    Arce, Begona
    Rivero, Belen
    Madero, Luis
    Lassaletta, Alvaro
    [J]. NEURO-ONCOLOGY, 2024, 26
  • [8] Intrahepatic plexiform neurofibroma in neurofibromatosis 1
    Isolina Vilas-Ferrol
    Miguel Hernández-Giménez
    M. Isabel Moya-García
    M. Antonia Menargues-Irles
    Carlos Muñoz-Núñez
    Enrique Poblet-Martinez
    [J]. Pediatric Radiology, 1998, 28 : 733 - 733
  • [9] Intrahepatic plexiform neurofibroma in neurofibromatosis 1
    Vilas-Ferrol, I
    Hernandez-Gimenez, M
    Moya-Garcia, MI
    Menargues-Irles, MA
    Munoz-Nunez, C
    Poblet-Martinez, E
    [J]. PEDIATRIC RADIOLOGY, 1998, 28 (09) : 733 - 733
  • [10] An evaluation of selumetinib for the treatment of neurofibromatosis type 1-associated symptomatic, inoperable plexiform neurofibromas
    Metrock, Laura K.
    Lobbous, Mina
    Korf, Bruce
    [J]. EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2021, 6 (04): : 239 - 246